ITMI992520A0 - Macrolidi - Google Patents

Macrolidi

Info

Publication number
ITMI992520A0
ITMI992520A0 IT99MI002520A ITMI992520A ITMI992520A0 IT MI992520 A0 ITMI992520 A0 IT MI992520A0 IT 99MI002520 A IT99MI002520 A IT 99MI002520A IT MI992520 A ITMI992520 A IT MI992520A IT MI992520 A0 ITMI992520 A0 IT MI992520A0
Authority
IT
Italy
Prior art keywords
macrolids
Prior art date
Application number
IT99MI002520A
Other languages
English (en)
Inventor
Francois Navarro
Samuel Petit
Guy Stone
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITMI992520(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ITMI992520A0 publication Critical patent/ITMI992520A0/it
Publication of ITMI992520A1 publication Critical patent/ITMI992520A1/it
Application granted granted Critical
Publication of IT1319701B1 publication Critical patent/IT1319701B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IT1999MI002520A 1998-12-07 1999-12-02 Procedimento per stabilizzare un macrolide polienicoed ed unparticolare macrolide ottenuto in forma cristallina IT1319701B1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (3)

Publication Number Publication Date
ITMI992520A0 true ITMI992520A0 (it) 1999-12-02
ITMI992520A1 ITMI992520A1 (it) 2001-06-02
IT1319701B1 IT1319701B1 (it) 2003-10-27

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999MI002520A IT1319701B1 (it) 1998-12-07 1999-12-02 Procedimento per stabilizzare un macrolide polienicoed ed unparticolare macrolide ottenuto in forma cristallina

Country Status (38)

Country Link
US (5) US6605613B2 (it)
EP (4) EP2279751A3 (it)
JP (3) JP3805625B2 (it)
KR (2) KR100695834B1 (it)
CN (2) CN1876657B (it)
AR (3) AR026102A1 (it)
AT (1) ATE365051T1 (it)
AU (1) AU759219B2 (it)
BE (1) BE1012869A3 (it)
BR (1) BR9915986A (it)
CA (3) CA2732620C (it)
CO (1) CO4980847A1 (it)
CY (1) CY1106870T1 (it)
CZ (2) CZ303006B6 (it)
DE (1) DE69936352T3 (it)
DK (1) DK1137439T4 (it)
ES (1) ES2288033T5 (it)
FR (1) FR2786771B1 (it)
GB (2) GB9826882D0 (it)
HK (1) HK1038889B (it)
HU (2) HU230174B1 (it)
ID (1) ID29250A (it)
IL (1) IL143092A0 (it)
IT (1) IT1319701B1 (it)
MY (2) MY127579A (it)
NO (2) NO332698B1 (it)
NZ (2) NZ511936A (it)
PE (1) PE20001333A1 (it)
PL (2) PL208854B1 (it)
PT (1) PT1137439E (it)
RU (1) RU2243769C2 (it)
SG (1) SG151072A1 (it)
SI (1) SI1137439T2 (it)
SK (2) SK287325B6 (it)
TR (2) TR200201428T2 (it)
TW (2) TWI248938B (it)
WO (1) WO2000033878A2 (it)
ZA (1) ZA200104360B (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
KR20040086369A (ko) 2002-02-13 2004-10-08 비오갈 기오기스제르갸르 알티. 바이오매터로부터 마크롤라이드를 추출하는 방법
KR101131794B1 (ko) * 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
KR20050114262A (ko) 2003-03-31 2005-12-05 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 결정화 및 정제
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220357B2 (en) 2003-07-24 2007-05-22 Teva Gyógyszergyár Zártkörúen Múkó´dó´Résvénytársaság Method of purifying macrolides
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US20070255197A1 (en) * 2003-12-10 2007-11-01 Acrux Dds Pty Ltd Method of Treatment for Undesired Effect Following Transdermal or Topical Drug Delivery
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
AU2006213673A1 (en) 2005-02-09 2006-08-17 Santen Pharmaceutical Co., Ltd. Formulations for ocular treatment
KR20080077147A (ko) * 2005-12-07 2008-08-21 와이어쓰 결정성 라파마이신의 제조 방법 및 시차 주사 열량계를사용하는 라파마이신 화합물의 결정화도의 측정 방법
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
CN101340901A (zh) * 2005-12-20 2009-01-07 惠氏公司 通过控制药物物质杂质控制cci-779剂型稳定性
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
JP2013529224A (ja) * 2010-06-07 2013-07-18 テリック，インコーポレイテッド 結晶性エザチオスタット塩酸塩非溶媒和物
JP5985474B2 (ja) * 2010-08-04 2016-09-06 メリル ライフ サイエンシズ ピーブィティ．エルティディ 抗増殖特性を有する新規４２−ｏ−（ヘテロアルコキシアルキル）ラパマイシン化合物の調製プロセス
EP2640730B1 (en) 2010-11-19 2019-08-07 Biocon Limited Processes for preparation of everolimus and intermediates thereof
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (it) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
WO2017018433A1 (ja) 2015-07-28 2017-02-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法
EP3342410A4 (en) * 2015-08-28 2019-04-24 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION WITH RAPAMYCIN OR DERIVATIVES THEREOF
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
US20190290631A1 (en) 2016-05-27 2019-09-26 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
US11814397B2 (en) 2020-03-27 2023-11-14 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3108192B2 (ja) 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ES2258763T3 (es) 1992-10-13 2006-09-01 Wyeth Carbamatos de rapamicina.
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
WO1996041807A1 (en) 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
JP3942641B2 (ja) * 1996-07-30 2007-07-11 ノバルティス アクチエンゲゼルシャフト サイクロスポリンａおよび４０―ｏ―（２―ヒドロキシエチル）―ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
WO1998033482A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
US7572804B2 (en) 2009-08-11
IL143092A0 (en) 2002-04-21
EP1743657A2 (en) 2007-01-17
JP2005200429A (ja) 2005-07-28
HK1038889B (zh) 2008-01-25
BR9915986A (pt) 2001-09-04
US20090270441A1 (en) 2009-10-29
HU230174B1 (hu) 2015-09-28
AR026102A1 (es) 2003-01-29
ES2288033T3 (es) 2007-12-16
AU1657300A (en) 2000-06-26
HUP0104489A2 (hu) 2002-03-28
KR20060096477A (ko) 2006-09-11
HK1038889A1 (en) 2002-04-04
TWI270550B (en) 2007-01-11
KR100695834B1 (ko) 2007-03-19
NO334612B1 (no) 2014-04-22
JP5043308B2 (ja) 2012-10-10
US7741338B2 (en) 2010-06-22
CA2651609A1 (en) 2000-06-15
TR200201428T2 (tr) 2002-12-23
TWI248938B (en) 2006-02-11
GB9904934D0 (en) 1999-04-28
CA2732620C (en) 2013-08-06
DE69936352D1 (de) 2007-08-02
SG151072A1 (en) 2009-06-29
NZ511936A (en) 2003-10-31
CA2351580C (en) 2012-03-20
NZ527781A (en) 2004-11-26
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
MY120594A (en) 2005-11-30
CN1876657B (zh) 2013-01-09
US6605613B2 (en) 2003-08-12
US20020032213A1 (en) 2002-03-14
DE69936352T3 (de) 2012-05-03
ZA200104360B (en) 2002-01-16
EP1137439B2 (en) 2011-11-23
HUP0104489A3 (en) 2004-05-28
DK1137439T4 (da) 2012-03-19
MY127579A (en) 2006-12-29
US6852729B2 (en) 2005-02-08
FR2786771B1 (fr) 2002-12-27
SK286688B6 (sk) 2009-03-05
GB9826882D0 (en) 1999-01-27
KR20010101128A (ko) 2001-11-14
IT1319701B1 (it) 2003-10-27
AR054444A2 (es) 2007-06-27
PL196627B1 (pl) 2008-01-31
PT1137439E (pt) 2007-09-25
NO20121113L (no) 2001-05-16
US20050107418A1 (en) 2005-05-19
SK7662001A3 (en) 2001-12-03
US20080161334A1 (en) 2008-07-03
JP2002531527A (ja) 2002-09-24
AU759219B2 (en) 2003-04-10
SK287325B6 (sk) 2010-07-07
BE1012869A3 (fr) 2001-04-03
US20030191148A1 (en) 2003-10-09
RU2243769C2 (ru) 2005-01-10
WO2000033878A3 (en) 2000-11-02
EP2279751A2 (en) 2011-02-02
EP2269651A3 (en) 2011-03-09
TW200540179A (en) 2005-12-16
CZ20012001A3 (cs) 2001-09-12
JP3805625B2 (ja) 2006-08-02
CZ302210B6 (cs) 2010-12-22
US7297703B2 (en) 2007-11-20
NO20012424L (no) 2001-05-16
ID29250A (id) 2001-08-16
DE69936352T2 (de) 2008-02-14
CA2351580A1 (en) 2000-06-15
EP1137439A2 (en) 2001-10-04
CN1261163C (zh) 2006-06-28
TR200101416T2 (tr) 2002-01-21
EP1137439B1 (en) 2007-06-20
PL208854B1 (pl) 2011-06-30
ES2288033T5 (es) 2012-04-10
EP2269651A2 (en) 2011-01-05
CN1374872A (zh) 2002-10-16
CZ303006B6 (cs) 2012-02-22
FR2786771A1 (fr) 2000-06-09
EP1743657A3 (en) 2007-03-28
CN1876657A (zh) 2006-12-13
PE20001333A1 (es) 2000-12-12
WO2000033878A2 (en) 2000-06-15
ATE365051T1 (de) 2007-07-15
CA2732620A1 (en) 2000-06-15
HU228939B1 (en) 2013-07-29
JP2006111637A (ja) 2006-04-27
CO4980847A1 (es) 2000-11-27
ITMI992520A1 (it) 2001-06-02
PL348333A1 (en) 2002-05-20
EP2279751A3 (en) 2011-02-16
NO20012424D0 (no) 2001-05-16
AR048073A2 (es) 2006-03-29
NO332698B1 (no) 2012-12-10
JP5165199B2 (ja) 2013-03-21
SI1137439T1 (sl) 2008-06-30
SI1137439T2 (sl) 2012-05-31

Similar Documents

Publication Publication Date Title
ATE341990T1 (de) Sigmidoskop
IS5372A (is) Gasmyndunarbúnaður
NO20010382L (no) Agglutineringsundersökelse
NO994700D0 (no) Nödunnsetningsinnretning
NO20005960L (no) Differensialinjektor
NO20004431D0 (no) Glysintransportinhibitorer
DE69904335T2 (de) Aminomethylcarbonsäurederivate
NO996385D0 (no) Kveileroersystem
NO20010715L (no) Fenylyantinderivater
DE69905536T2 (de) Gyriconscheibe
DE69939653D1 (de) Erkstoff
ATE262513T1 (de) Benzoylpyridazine
NO20005934D0 (no) Evakueringsrefuge
DE69903170D1 (de) Organometallzusammensetzungen
DE59807217D1 (de) Nadellager
IT1306269B1 (it) Elettromandrino
DE1118098T1 (de) Mehrfachflussigelektrosprühschnittstelle
DE19842103B4 (de) Stanznietzuführung
NO20004740L (no) Paroksetinblandinger
DE69917702D1 (de) Filamentgarnaufwickelmaschine
DE29819079U1 (de) Kombuchalyophilisat
ATA126298A (de) Verpuffungsklappe
DE69901354D1 (de) Imidazol-N-Schwefeldifluoride
DE29809642U1 (de) Mürbehammer
DE29820409U1 (de) Jätharke